This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Distal muscular dystrophy (distal myopathy)Distal Muscular Dystrophy (Distal Myopathy)

ICD-10G71.0
Special Copayment ReductionV012 · 5 years
A. SynonymsDistal myopathy, distal muscular dystrophy
B. Adult onsetHigh — mostly adult onset; Nonaka and Miyoshi types begin in the 20s–30s, Welander and Udd (tibial myopathy) types in the 40s–60s
1. History1902 Gowers described a familial myopathy characterized by distal weakness of the hands and feet; 1951 Welander reported autosomal dominant distal myopathy in Swedish families; subsequently Nonaka (1981), Miyoshi (1986), Udd (1993), and others established the subtype classification
2. CausesMultiple genes (GNE, DYSF, MATR3, VCP, MYH7, TIA1, HSPB8, FLNC, ACTN2, etc.); distal weakness of the feet and hands appears before proximal weakness
3. GeneticsAutosomal dominant (Welander, Udd/tibial, VCP, MATR3, TIA1, etc.) or autosomal recessive (Nonaka/GNE, Miyoshi/DYSF); GNE myopathy is relatively common in East Asia, including Korea
4. EpidemiologyOverall prevalence of distal myopathies difficult to estimate; Welander type 1/10,000 in Scandinavia; GNE myopathy (Nonaka type) estimated at 700–800 patients worldwide in total; GNE myopathy relatively common in Korea
5. PathophysiologyBy subtype: GNE enzyme deficiency (impaired sialic acid synthesis) → abnormal glycosylation of the sarcolemma; DYSF deficiency → impaired membrane repair; MYH7 and FLNC mutations → abnormal myofibrillar structure; RNA-binding protein (TIA1) variants → abnormal stress granules
6. SymptomsFoot drop, weak ankle dorsiflexion (tibialis anterior), weak finger and wrist extension, missteps on stairs; depending on subtype, selective involvement of the gastrocnemius (Miyoshi type) or tibialis anterior (Nonaka type)
7. SignsFoot drop, equinus gait, impaired finger extension; mildly to moderately elevated serum CK (markedly elevated in Miyoshi type); rimmed vacuoles on muscle biopsy — characteristic of Nonaka and Welander types
8. ScreeningIn adults with unexplained foot drop or distal weakness: serum CK + EMG + muscle MRI; after checking family history, NGS panel genetic testing
9. DiagnosisSerum CK → EMG and nerve conduction → muscle MRI (pattern of distal involvement) → NGS muscle panel → muscle biopsy (rimmed vacuoles, immunohistochemistry)
10. TreatmentNo approved disease-modifying therapy; GNE myopathy — clinical trials of sialic acid and ManNAc supplementation; supportive treatment (AFO, physical therapy); cardiac treatment when cardiomyopathy is present (some subtypes)
11. PrognosisMostly slowly progressive; walking ability can be maintained for a long time, but orthoses or a wheelchair are eventually needed; risk of sudden death in subtypes with cardiomyopathy (MYH7, FLNC); respiratory muscle involvement also occurs in some subtypes
12. PreventionGenetic counseling; prenatal and preimplantation genetic diagnosis; early management of foot drop to prevent falls and injuries; regular cardiac monitoring in subtypes with cardiomyopathy
References10 key PMIDs/DOIs

1. History

Distal muscular dystrophy (hereafter distal myopathy) entered history in 1902 when the British neurologist William Gowers first described cases of familial myopathy characterized mainly by distal weakness of the hands and feet. Gowers argued that this disease is a distinct entity because, unlike most muscular dystrophies, weakness begins first in the extremities (distally).

In 1951, the Swedish neurologist Lisa Welander reported on a large scale an autosomal dominant distal myopathy with onset in adulthood (middle to old age) in families of Scandinavian descent from Sweden and Finland, establishing the name Welander distal myopathy. This lineage showed a distinctive phenotype in which the small muscles of the hand, particularly the finger and wrist extensors, are affected first.

In 1981, Nonaka et al. in Japan described in Japanese families an autosomal recessive distal myopathy subtype characterized by tibialis anterior involvement and rimmed vacuoles on muscle biopsy (Nonaka distal myopathy), and in 1986 Miyoshi et al. reported a separate recessive form characterized by involvement of the gastrocnemius and posterior calf muscles (Miyoshi myopathy). Since the 2000s, as various causative genes such as GNE, DYSF, MYH7, TIA1, MATR3, VCP, and FLNC have been identified, distal myopathy has come to be understood not as a single disease but as a group of diseases with great clinical and genetic heterogeneity.

GNE myopathy (formerly Nonaka distal myopathy or IBM2) was shown in 2001 to be caused by mutations in the GNE gene, which encodes a sialic acid biosynthetic enzyme, and founder effects are known in Jewish and East Asian populations. The proportion of GNE myopathy is high among patients with distal myopathy in East Asia, including Korea, and it is continually reported by Korean neuromuscular centers.

2. Causes

Distal myopathy is not a single disease but a clinically and genetically heterogeneous group of diseases caused by mutations in multiple genes. The major causative genes and corresponding subtypes known to date are as follows.

Autosomal recessive forms: GNE (UDP-GlcNAc 2-epimerase/N-acetylmannosamine kinase) — GNE myopathy (Nonaka type, IBM2); caused by deficiency of an enzyme in the sialic acid synthesis pathway. DYSF (dysferlin) — Miyoshi myopathy type 1, overlapping with LGMD-R2; deficiency of a membrane repair protein.

Autosomal dominant forms: MYH7 (beta myosin heavy chain) — Laing distal myopathy; risk of associated cardiomyopathy. MATR3 (matrin-3) — vocal cord and pharyngeal distal myopathy (VCPDM); accompanied by vocal cord paralysis and dysphagia. VCP (valosin-containing protein p97) — inclusion body myopathy, Paget disease and frontotemporal dementia (IBMPFD); multisystem involvement. TIA1 (T-cell cytotoxic granule-associated RNA-binding protein 1) — Welander distal myopathy; concentrated in Scandinavian populations. HSPB8 (small heat shock protein 8) — upper-limb distal myopathy overlapping with Charcot-Marie-Tooth type 2L. FLNC (filamin-C) — distal FLNC-related myopathy; risk of associated cardiomyopathy. ACTN2 (actinin-2) — distal involvement possible.

By function, these genes fall into several categories, including a sialic acid biosynthesis enzyme (GNE), a membrane repair protein (DYSF), myofibrillar structural proteins (MYH7, FLNC, ACTN2), an RNA-binding/stress granule protein (TIA1), and a protein degradation pathway protein (VCP).

3. Genetics

The inheritance pattern of distal myopathy varies by subtype, with both autosomal dominant and recessive forms. Autosomal recessive forms: these include GNE myopathy (GNE mutations) and Miyoshi myopathy (DYSF mutations). Patients with recessive forms carry mutations in both alleles (homozygous or compound heterozygous), and carrier parents are asymptomatic. Autosomal dominant forms: these include the Welander type (TIA1), Laing type (MYH7), MATR3-related, VCP-related and FLNC-related forms, which are transmitted from an affected parent to a child with 50% probability. De novo mutations are not uncommon.

GNE myopathy shows a pronounced founder effect in certain populations. The GNE p.M743T (c.2228T>C) mutation in Iranian and Iraqi Jews and the p.V572L (c.1714G>T) mutation in Japanese are known founder mutations. GNE myopathy has also been reported in Korean patients, with a variety of mutations identified. VCP-related disease (IBMPFD) is autosomal dominant and may present simultaneously with inclusion body myopathy (IBM), Paget disease of bone and frontotemporal dementia, so the possibility of multisystem involvement should be fully explained during genetic counseling.

NGS-based muscle panels or whole-exome analysis are the standard for molecular diagnosis, and targeted genetic testing is recommended particularly for family members of patients with confirmed GNE myopathy.

4. General epidemiology

The overall prevalence of distal myopathy is difficult to estimate accurately because of the diversity of subtypes. Each subtype is individually rare, and the relative frequency of specific subtypes varies greatly by country and ethnicity. Welander distal myopathy has a prevalence of about 1/10,000 in Scandinavian (Swedish, Finnish) populations and is the most common distal myopathy in that region. About 700–800 patients with GNE myopathy (Nonaka type) have been reported worldwide, but it is presumed to be substantially underdiagnosed. In Japan, GNE myopathy is the most common distal myopathy, and it is also diagnosed relatively frequently in Korea.

Miyoshi myopathy (DYSF-related) is relatively common in Japan, and numerous cases have been reported worldwide. IBMPFD (VCP-related) is a very rare disease, with about 200 families reported worldwide. Laing distal myopathy (MYH7) has been reported in tens to hundreds of patients worldwide. Sex differences are not pronounced in most subtypes, but some reports of Miyoshi myopathy show earlier onset and faster progression in males.

Situation in Korea: in Korea, GNE myopathy is the most frequently reported distal myopathy, followed by rarely diagnosed DYSF-related Miyoshi myopathy and the MYH7-related Laing type. It is classified and managed as G71.0 in the rare disease registration system.

5. Pathophysiology

The pathophysiology of distal myopathy differs by subtype, and some aspects have not yet been fully elucidated.

GNE myopathy (sialic acid deficiency mechanism): The GNE protein is a key sialic acid synthesis enzyme with dual enzymatic activity, UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. When enzyme activity is reduced by GNE mutations, biosynthesis of sialic acid (N-acetylneuraminic acid) decreases, and consequently sialylation of the sarcolemma and muscle-related glycoproteins becomes insufficient. The sarcolemma with reduced sialic acid shows structural and functional abnormalities, and as a result muscle fiber degeneration progresses. Based on this mechanism, supplementation therapy with sialic acid and its precursor (ManNAc, N-acetylmannosamine) is being studied.

Miyoshi myopathy (membrane repair deficiency mechanism): Dysferlin (DYSF) is a key protein in the 'membrane repair' process, in which vesicles move to and fuse at sites of sarcolemmal injury to seal the membrane. In dysferlin deficiency, microinjuries accumulate during muscle contraction, accelerating muscle fiber loss.

MYH7- and FLNC-related (myofibrillar structural abnormality): Beta myosin heavy chain (MYH7) is the main contractile protein of cardiac muscle and slow-twitch skeletal muscle fibers (type I). MYH7 mutations impair the mechanical function of myofibrils and cause abnormalities of the ubiquitin-proteasome and autophagy pathways. Filamin-C (FLNC) mutations also cause abnormalities of the myofibrillar network structure and are associated with protein aggregation.

TIA1-, MATR3- and VCP-related (RNA/protein processing abnormality): TIA1 is an RNA-binding protein involved in stress granule formation; when mutated, impaired granule resolution and protein aggregation occur. VCP (p97) is an ATP-dependent protein degradation chaperone that directs damaged proteins to the proteasome. When VCP function is abnormal, inclusion body formation and impaired autophagy occur across muscle, bone and brain, producing the multisystem phenotype of IBMPFD.

6. Symptoms

The common feature of distal myopathies is that muscle weakness begins in the distal parts of the limbs before the proximal parts. The specific muscles involved and age of onset differ by subtype.

GNE myopathy (Nonaka type): Onset at age 20–40. Weakness and atrophy of the anterior lower leg (tibialis anterior, peroneal muscles) appear first, and foot drop and gait abnormality due to weak ankle dorsiflexion are the initial symptoms. A characteristic feature is that the quadriceps are relatively spared until late in the course. Involvement then spreads to the distal upper limbs and upper arm muscles. Serum CK is normal to mildly elevated.

Miyoshi myopathy (DYSF type): Onset at age 15–25. It begins with weakness of the posterior distal lower-leg muscles (gastrocnemius, soleus), and difficulty with heel rise is the initial symptom. Rapid atrophy of the gastrocnemius makes the calves thin. CK is markedly elevated (tens to hundreds of times normal). Proximal involvement occurs late, and some patients present with an LGMD-R2 phenotype.

Welander type (TIA1): Onset at age 40–60. It begins with weakness of the small muscles of the hand, especially the finger extensors (extensor digitorum), making fine hand movements such as buttoning and writing difficult. It gradually progresses to the distal foot. CK is mildly elevated or normal.

Udd/tibial myopathy (titin-MYH7-related): Onset in the 40s–60s. It often begins with foot drop due to tibialis anterior involvement, and some patients also have nonspecific proximal symptoms.

7. Signs

Major signs of distal myopathy on physical examination: Foot drop: weak ankle dorsiflexion causes the forefoot to drop when walking, with a high risk of missteps on stairs or falls. Inability to walk on the heels (heel walking): characteristic of subtypes involving the tibialis anterior (GNE myopathy, tibial myopathy). Inability to stand on the heels (heel raise): characteristic of subtypes involving the gastrocnemius and soleus (Miyoshi myopathy). Weak finger extension: appears with atrophy of the dorsal hand muscles in the Welander type. Gastrocnemius atrophy (Miyoshi type) or tibialis anterior atrophy (GNE type) is visibly evident.

Laboratory findings: serum CK ranges from normal to hundreds of times normal depending on subtype. Marked CK elevation in Miyoshi myopathy, mild to moderate elevation in GNE myopathy, and normal to mild elevation in the Welander type. Electromyography shows myopathic changes (small polyphasic MUAPs, spontaneous activity potentials). Nerve conduction is normal, allowing differentiation from peripheral neuropathy. Muscle MRI: the pattern of selective fatty infiltration of muscles by subtype plays a key role in differential diagnosis. Muscle biopsy: rimmed vacuoles are a characteristic finding in GNE myopathy and the Welander type.

In VCP-related IBMPFD, Paget disease of bone (thickening and pain of the skull and long bones) and frontotemporal dementia (behavioral change, language impairment) may coexist, so bone metabolism and cognitive function are assessed concurrently. In MYH7- and FLNC-related distal myopathy, cardiomyopathy may coexist, so echocardiographic monitoring is needed.

8. Screening

Screening for distal myopathy begins when progressive distal weakness, such as unexplained foot drop, ankle weakness or weak finger extension, appears in an adult. This must be differentiated from peripheral neuropathy (Charcot-Marie-Tooth disease, compression neuropathy), motor neuron disease (early ALS), inflammatory myopathy and others.

First-line screening: serum CK measurement — if the level is normal or mildly elevated, suspect neuropathy or a mild myopathy; if elevated tens to hundreds of times, suspect DYSF-related myopathy first. Electromyography and nerve conduction studies — the combination of myopathic changes and normal nerve conduction strongly suggests distal myopathy. Second-line screening: muscle MRI — the pattern of affected muscles (tibialis anterior vs. gastrocnemius vs. intrinsic muscles) and the distribution of fatty infiltration are very useful for predicting the subtype. Third-line screening: NGS muscle panel genetic testing.

Family history assessment: the presence of similarly affected individuals in the same family and the inheritance pattern (dominant or recessive) are identified to establish an appropriate genetic testing strategy. In families with GNE myopathy, early diagnosis is possible even in asymptomatic siblings through GNE gene testing.

9. Diagnosis

The diagnosis of distal myopathy is established by integrated assessment of clinical findings, laboratory tests, imaging, genetic analysis and, if needed, muscle biopsy.

Step 1 — clinical assessment and serum CK: determine age of onset, distribution of affected muscles (anterior vs. posterior distal, upper vs. lower limb), family history and inheritance pattern. Step 2 — electromyography and nerve conduction: confirm myopathic changes and differentiate from neuropathy. Step 3 — muscle MRI (T1, STIR): analyze the pattern of fatty replacement in distal muscles; early involvement of the tibialis anterior and peroneal muscles is characteristic of GNE myopathy, and early involvement of the gastrocnemius and soleus is characteristic of the Miyoshi type. Step 4 — NGS muscle panel or whole-exome analysis: includes major genes such as GNE, DYSF, MYH7, TIA1, MATR3, VCP and FLNC. Molecular diagnostic yield 50–70%. Step 5 — muscle biopsy (when the genetic diagnosis is unclear): identification of rimmed vacuoles on H&E and Gomori trichrome staining is a specific finding of GNE myopathy and the Welander type. Electron microscopy shows intranuclear and cytoplasmic inclusions containing 15–18 nm filaments. Dysferlin deficiency in Miyoshi myopathy is confirmed by immunofluorescence with dysferlin antibodies.

Differential diagnosis: in unilateral foot drop, exclude common peroneal nerve compression. In bilateral foot drop, differentiation from ALS, CMT, GBS and polyradiculoneuropathy is needed. Inflammatory myopathies (dermatomyositis, inclusion body myositis) are differentiated by clinical course, histologic findings and autoantibodies.

10. Treatment

Currently there is no FDA- or EMA-approved disease-modifying therapy for any subtype of distal myopathy. Supportive care is the foundation of treatment, and clinical trials are most active for GNE myopathy.

Research specific to GNE myopathy: Based on the sialic acid deficiency theory, clinical trials of oral sialic acid (N-acetylneuraminic acid) supplementation and ManNAc (N-acetylmannosamine) supplementation were conducted in the 2010s. Small studies suggested possible partial stabilization of muscle function, but a large phase 3 trial did not meet its primary outcome measure, and this has not led to an approved therapy to date. Preclinical studies of gene therapy (AAV-based) and mRNA therapy are under way.

Supportive care: Ankle-foot orthosis (AFO): correction of foot drop and fall prevention. Walking aids (cane, walker). Physical therapy (strength training, prevention of joint contractures, balance training). Occupational therapy (alternative strategies for fine hand movements, assistive devices). Creating a fall-prevention environment (non-slip flooring, installing handrails). Subtypes with associated cardiomyopathy (MYH7-, FLNC-related): ACE inhibitors and beta-blockers; consider an ICD (implantable cardioverter-defibrillator) if there is a risk of ventricular tachycardia. With respiratory muscle involvement: initiation of nocturnal BiPAP.

Treatment of VCP-IBMPFD: bisphosphonates for Paget disease of bone, and symptomatic management of dementia. Drugs that enhance the proteasome-autophagy pathway are currently in preclinical studies.

11. Prognosis

Most distal myopathies progress slowly, allowing independent walking to be maintained for a long time. However, there is considerable variation by subtype. GNE myopathy: progression is very slow, and some patients retain some walking ability even 20–30 years after onset. However, foot drop and falls due to weakness of the tibialis anterior and peroneal muscles are the main causes of morbidity, and eventually most require walking aids or a wheelchair by their 60s–70s. Sparing of the quadriceps is a feature of GNE myopathy that favors maintenance of walking.

Miyoshi myopathy: gastrocnemius atrophy progresses rapidly, but loss of walking ability takes decades. Cardiomyopathy is rare. Welander type: loss of hand function is the main cause of disability, and walking is mostly preserved. Progression is very slow. MYH7- and FLNC-related forms: when cardiomyopathy coexists, there is a risk of sudden death, so regular cardiac monitoring and early ICD implantation greatly determine prognosis. VCP-IBMPFD: when dementia coexists, quality of life declines rapidly, and the fracture risk of Paget disease of bone and the risk of pneumonia affect prognosis.

12. Prevention

Fundamental prevention of distal myopathy is achieved through genetic counseling and prenatal or preimplantation genetic diagnosis. Recessive forms (GNE, DYSF): after carrier parents are identified, prenatal genetic testing (CVS, amniocentesis) or PGT-M can be performed for offspring. Heterozygous carriers are asymptomatic, so active genetic counseling is important when there is a family history. Dominant forms (TIA1, MYH7, MATR3, VCP, FLNC): 50% risk of disease in children of an affected parent; preventable by PGT-M or prenatal diagnosis.

Secondary prevention: Prevention of foot drop and falls: prevent fractures and injuries from falls with early prescription of an AFO, improvement of the walking environment and balance training. Early detection of cardiomyopathy: in MYH7- and FLNC-related subtypes, perform regular echocardiography from the time of diagnosis and monitor the risk of ventricular tachycardia to determine the timing of ICD implantation. Monitoring of respiratory function: some subtypes (FLNC-, VCP-related) may involve the respiratory muscles, so FVC is measured regularly. Nutritional management: in subtypes with dysphagia (MATR3-related VCPDM), provide aspiration prevention education and dietary adjustment.

References

  1. Udd B. Distal myopathies. Curr Neurol Neurosci Rep. 2014;14(3):434. PMID: 24414052
  2. Nonaka I, Sunohara N, Ishiura S, Satoyoshi E. Familial distal myopathy with rimmed vacuole and lamellar (myeloid) body formation. J Neurol Sci. 1981;51(1):141-155. PMID: 6166229
  3. Miyoshi K, Kawai H, Iwasa M, Kusaka K, Nishino H. Autosomal recessive distal muscular dystrophy as a new type of progressive muscular dystrophy. Brain. 1986;109(Pt 1):31-54. PMID: 3002596
  4. Nishino I, Noguchi S, Murayama K, et al. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. Neurology. 2002;59(11):1689-1693. PMID: 12473754
  5. Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet. 2001;29(1):83-87. PMID: 11528398
  6. Hackman P, Vihola A, Haravuori H, et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet. 2002;71(3):492-500. PMID: 12145742
  7. Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36(4):377-381. PMID: 15034582
  8. Klar J, Sobol M, Melberg A, et al. Welander distal myopathy caused by an ancient founder mutation in TIA1 associated with autophagic rimmed vacuoles. Brain. 2013;136(Pt 3):853-865. PMID: 23436497
  9. Agrawal PB, Joshi M, Marinakis NS, et al. Expanding the phenotype associated with the NEFL mutation: neuromuscular disease in a family with overlapping myopathic and neurogenic findings. JAMA Neurol. 2014;71(11):1413-1420. PMID: 25244487
  10. Tasca G, Udd B. Hereditary myopathy with early respiratory failure (HMERF) and other TTN-related myopathies. Neuromuscul Disord. 2018;28(12):969-977. PMID: 30396762